Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017

This article was originally published in The Pink Sheet Daily

Executive Summary

The partners’ flexibility allows them, together and separately, to establish solid footholds in a still-evolving field with plenty of potential but also uncertainties.

You may also be interested in...

Biosimilars Wedge Issue: Actavis Splits With GPhA In Supporting Calif. Notification Bill

PhRMA, BIO and Abbvie also back California bill that would require pharmacists to notify physicians of biosimilar substitution while GPhA, Boehringer Ingelheim and Novartis oppose it.

Korean Companies Step Up Development Of Enbrel Biosimilars As Amgen Ramps Up Its Pipeline

After halting trials of its Rituxan biosimilar last year, Samsung Bioepis is focusing on its Enbrel biosimilar and has begun Phase I trials. Other Korean pharma are developing biosimilars of Enbrel, with Hanwha expecting approval in Korea this year.

GPhA Battles State Biosimilar Bills; 5 Passed, 10 Rejected

Generic Pharmaceutical Association wants to assure legislation on biologics substitution does not impose more restrictions than required for small molecules; opposes measures pushed by Amgen and Genentech.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts